Literature DB >> 10396073

Activation molecules on human myeloma cells.

B Klein1, X Y Li, Z Y Lu, M Jourdan, K Tarte, J Brochier, E Claret, J Wijdenes, J F Rossi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10396073     DOI： 10.1007/978-3-642-60162-0_41

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  4 in total

1.  Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Authors:  K Mahtouk; F W Cremer; T Rème; M Jourdan; M Baudard; J Moreaux; G Requirand; G Fiol; J De Vos; M Moos; P Quittet; H Goldschmidt; J-F Rossi; D Hose; B Klein
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

2.  The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

Authors:  Jérôme Moreaux; Friedrich W Cremer; Thierry Reme; Marc Raab; Karene Mahtouk; Philine Kaukel; Veronique Pantesco; John De Vos; Eric Jourdan; Anna Jauch; Eric Legouffe; Marion Moos; Genevieve Fiol; Hartmut Goldschmidt; Jean François Rossi; Dirk Hose; Bernard Klein
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

3.  Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Authors:  Karène Mahtouk; Dirk Hose; Pierre Raynaud; Michael Hundemer; Michel Jourdan; Eric Jourdan; Veronique Pantesco; Marion Baudard; John De Vos; Marion Larroque; Thomas Moehler; Jean-Francois Rossi; Thierry Rème; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

4.  Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

Authors:  J-F Rossi; J Moreaux; D Hose; G Requirand; M Rose; V Rouillé; I Nestorov; G Mordenti; H Goldschmidt; A Ythier; B Klein
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.